Efficacy of plerixafor in CD34+ stem cell mobilization in healthy pediatric stem cell donors.

BACKGROUND AND

OBJECTIVES

Efficient stem cell collection from pediatric donors is a common challenge for allogeneic hematopoietic stem cell transplants (HSCT). The addition of plerixafor, a CXCR4 antagonist to standard stem cell mobilization regimens has shown success. We describe our experience with the usage of a single dose of plerixafor in addition to granulocyte colony-stimulating factor (G-CSF) in healthy pediatric stem cell donors for patients undergoing HSCT.

MATERIALS AND

METHODS

A retrospective review of the safety and efficacy of plerixafor, used in pediatric stem cell donors for aiding stem cell mobilization, was done. Data from 14 pediatric donors who received plerixafor in addition to standard G-CSF were studied.

RESULTS

Plerixafor was well tolerated by all donors with no major adverse effects. All donors showed robust peripheral blood stem cell mobilization, enabling an adequate stem cell collection with single apheresis, even in scenarios with an unfavorable donor/patient body weight ratio.

CONCLUSION

The use of plerixafor can be encouraged in pediatric donors to optimize apheresis outcomes.